Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?

Clinical Colorectal Cancer

Volumn 4, Issue SUPPL. 2, 2004, Pages

  Kabbinavar, Fairooz F ^a   Ellis, Lee M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Bevacizumab; Combination therapy; Hypertension; Leucovorin; Proteinuria; Vascular endothelial growth factor

Indexed keywords

ALBUMIN; ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; VASCULOTROPIN INHIBITOR;

ALBUMIN BLOOD LEVEL; ANGIOGENESIS; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLON DIVERTICULOSIS; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HEADACHE; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; LEUKOPENIA; METASTASIS; NEUTROPENIA; PROGNOSIS; PROTEINURIA; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; VOMITING; WOUND HEALING IMPAIRMENT;

EID: 7444252791     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2004.s.011     Document Type: Article

References (15)

1. Muhlhauser J, Merrill MJ, Pili R, et al. VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ Res 1995; 77:1077-1086.
2. Amaya H, Tanigawa N, Lu C, et al. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett 1997; 119:227-235.
3. Nakata S, Ito K, Fujimori M, et al. Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers. Int J Cancer 1998; 79:179-186.
4. Giantonio BJ, Catalano PJ, Meropol NJ et al. The addition of bevacizumab (anti-VEGF) to FOLFOX4 in previously treated advanced colorectal cancer (adv CRC): an updated interim analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. In: Proceedings of the 2004 Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, CA. Abstract #241.
5. Hurwitz H, Fehrenbacher L, Hainsworth J, et al. Bevacizumab in combination with 5-flourouracil and leucovorin: a promising regimen for first-line metastatic colorectal cancer. In: Proceedings of the 2004 Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, CA. Abstract #286.
6. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-65.
7. Freyer G, Rougier P, Bugat R, et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups. Br J Cancer 2000; 83:431-437.
8. Rougier P, Mitry E, Cunningham D, et al. Is age a prognostic factor of toxicity and efficacy in patients (pts) with metastatic colorectal cancer (MCRC) receiving irinotecan in combination with 5FU/folinic acid (FA). Proc Am Soc Clin Oncol 2003; 22:267 (Abstract #1072).
9. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
10. Knight RD, Miller L, Elfring G, et al. Evaluation of age, gender, performance status (PS), and organ dysfunction as predictors of toxicity with first-line irinotecan (C), fluorouracil (F), leucovorin (L) therapy of metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2001; 20:534 (Abstract #534).
11. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
12. Kabbinavar F, Schultz J, McCleod M, et al. Results of a randomized, phase II controlled trial of bevacizumab in combination with 5-fluourouracil and leucovorin as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 2004; 23:249 (Abstract #3516).
13. Mass R, Fyfe G, Hambleton J, et al. Bevacizumab (Avastin) in combination with 5-FU/leucovorin improves survival in patients with metastatic colorectal cancer: a combined analysis. Proc Am Soc Clin Oncol 2004; 23:274 (Abstract #3616).
14. Avastin [package insert]. South San Francisco, CA: Genentech, 2004.
15. Hurwitz H. Integrating anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 2004; 4(suppl):S62-S68.